USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NANOMETICS, LLC
Address:
50 E 8TH ST, STE 6N
NEW YORK, NY 10003-6502
Phone:
N/A
URL:
N/A
EIN:
126024039
DUNS:
831297770
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $494,009.00 2
SBIR Phase II $2,595,637.00 1

Award List:

Organocatalysis for the Treatment of Sickle Cell Disease.

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$243,469.00
Agency:
HHS
Principal Investigator:
Steven Isaacman – 646-267-5720
Abstract:
DESCRIPTION (provided by applicant): One potential therapeutic approach to treat sickle cell disease (SCD) involves the administration of aryl aldehyde-containing small molecules that form Schiff base adducts with hemoglobin (HbS) and prevent sickling. Theutility of this approach is inherently… More

Schiff base forming sunscreen filters for long-wear UV protection

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$250,540.00
Agency:
HHS
Principal Investigator:
Steven Isaacman – 646-267-5720
Abstract:
DESCRIPTION (provided by applicant): Problem to be solved: Skin cancer is the most common of all cancers, accounting for nearly half of all reported cancer cases in the USA. According to the American Cancer Society (ACS), the best way to lower the risk ofnon-melanoma skin cancer is to practice sun… More

Organocatalysis for the treatment of sickle cell disease

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$2,595,637.00
Agency:
HHS
Principal Investigator:
Steven Isaacman – 646-801-3872
Abstract:
DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a global health issue that affects ~100,000 Americans and over 13 million people worldwide. The complexity of the disease dictates that a multimodal approach to treatment will likely be needed. SCD is manifested physiologically during… More